Schedule 13G ownership disclosure
Tarsus Pharmaceuticals Inc
Common Stock · CUSIP: 87650L103
Event date: 2025-03-31
- Filing-level shares
- 1,943,453
- Percent of class
- 4.7%
- Morgan Stanley
Shares: 1,943,453 · Class: 4.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000895421-25-000370
- Form type
- SCHEDULE 13G/A
- Filer
- MORGAN STANLEY
- CIK
- CIK 895421
- Filed
- May 07, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership